Johnson & Johnson: Janssen Reports Positive Top-Line Phase 3 Results for Ponesimod in Adults With Relapsing Multiple Sclerosis
July 25, 2019
July 25, 2019
TITUSVILLE, New Jersey, July 25 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
- Data Are Part of The OPTIMUM Study Comparing The Efficacy And Safety of Ponesimod And Aubagio in Adults With Relapsing Multiple Sclerosis
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive top-line results from the Phase 3 OPTIMUM study, which evaluated the . . .
* * *
- Data Are Part of The OPTIMUM Study Comparing The Efficacy And Safety of Ponesimod And Aubagio in Adults With Relapsing Multiple Sclerosis
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive top-line results from the Phase 3 OPTIMUM study, which evaluated the . . .